| Drug Name: | Doxepin (1668-19-5) |
|---|---|
| PubChem ID: | 667477 |
| SMILES: | CN(C)CC/C=C/1C2=CC=CC=C2COC3=CC=CC=C31 |
| InchiKey: | ODQWQRRAPPTVAG-GZTJUZNOSA-N |
| Therapeutic Category: | Antidepressive Agents, Central Nervous System Agents, Histamine Agents, Histamine Antagonists, Neurotransmitter Agents, Psychotropic Drugs |
| Molecular Weight (dalton) | : | 279.383 |
| LogP | : | 3.9624 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 2 |
| Hydrogen Bond Donor Count | : | 0 |
| Total Polar Surface Area | : | 12.47 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Toxicity And Inefficacy | CYP2D6 (P10635) | Toxicity in poor metabolisers@ inefficacy in ultrarapid metabolisers [ ADR Type 3 ] | Drugs in special patient groups: clinical importance of genomics in drug effects In: Carruthers GS, Hoffmann BB,Melmon KL, Nierenberg DW |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category